EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer

Cell Reports

Volumn 8, Issue 1, 2014, Pages 204-216

  Wee, ZhenNing ^a,c   Li, Zhimei ^a   Lee, PuayLeng ^a   Lee, ShuetTheng ^a   Lim, YoonPin ^b,c   Yu, Qiang ^a,b,d  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR 1; JANUS KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; STAT1 PROTEIN; TRANSCRIPTION FACTOR EZH2; 3-DEAZANEPLANOCIN; ADENOSINE; EZH2 PROTEIN, HUMAN; GAMMA INTERFERON RECEPTOR; INTERFERON RECEPTOR; POLYCOMB REPRESSIVE COMPLEX 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; MALE; MALIGNANT TRANSFORMATION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PROSTATIC NEOPLASMS; TUMOR CELL LINE; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; DRUG SENSITIVITY; GENE SILENCING; HUMAN TISSUE; IN VITRO STUDY; MONOTHERAPY; PROTEIN INDUCTION; RECEPTOR DOWN REGULATION;

ADENOSINE; ANIMALS; CELL LINE, TUMOR; HUMANS; INTERFERON-GAMMA; JANUS KINASES; MALE; MICE; MICE, NUDE; POLYCOMB REPRESSIVE COMPLEX 2; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

EID: 84904055873     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.05.045     Document Type: Article

References (54)

1. Bachmann I.M., Halvorsen O.J., Collett K., Stefansson I.M., Straume O., Haukaas S.A., Salvesen H.B., Otte A.P., Akslen L.A. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J.Clin. Oncol. 2006, 24:268-273.
2. Bernard D., Pourtier-Manzanedo A., Gil J., Beach D.H. Myc confers androgen-independent prostate cancer cell growth. J.Clin. Invest. 2003, 112:1724-1731.
3. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003, 22:5323-5335.
4. Bryant R.J., Cross N.A., Eaton C.L., Hamdy F.C., Cunliffe V.T. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 2007, 67:547-556.
5. Bulbul M.A., Huben R.P., Murphy G.P. Interferon-beta treatment of metastatic prostate cancer. J.Surg. Oncol. 1986, 33:231-233.
6. Cao Q., Yu J., Dhanasekaran S.M., Kim J.H., Mani R.S., Tomlins S.A., Mehra R., Laxman B., Cao X., Yu J., et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008, 27:7274-7284.
7. Cha T.L., Zhou B.P., Xia W., Wu Y., Yang C.C., Chen C.T., Ping B., Otte A.P., Hung M.C. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005, 310:306-310.
8. Chang C.J., Hung M.C. The role of EZH2 in tumour progression. Br. J. Cancer 2012, 106:243-247.
9. Crea F., Hurt E.M., Mathews L.A., Cabarcas S.M., Sun L., Marquez V.E., Danesi R., Farrar W.L. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol. Cancer 2011, 10:40.
10. Duhagon M.A., Hurt E.M., Sotelo-Silveira J.R., Zhang X., Farrar W.L. Genomic profiling of tumor initiating prostatospheres. BMC Genomics 2010, 11:324.
11. Gazin C., Wajapeyee N., Gobeil S., Virbasius C.M., Green M.R. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 2007, 449:1073-1077.
12. Gonzalez M.E., Li X., Toy K., DuPrie M., Ventura A.C., Banerjee M., Ljungman M., Merajver S.D., Kleer C.G. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 2009, 28:843-853.
13. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., Quist M.J., Jing X., Lonigro R.J., Brenner J.C., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
14. Gurel B., Iwata T., Koh C.M., Jenkins R.B., Lan F., Van Dang C., Hicks J.L., Morgan J., Cornish T.C., Sutcliffe S., et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod. Pathol. 2008, 21:1156-1167.
15. Hastie C. Interferon gamma, a possible therapeutic approach for late-stage prostate cancer?. Anticancer Res. 2008, 28(5B):2843-2849.
16. Jenkins R.B., Qian J., Lieber M.M., Bostwick D.G. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence insitu hybridization. Cancer Res. 1997, 57:524-531.
17. Kaur M., Cole M.D. MYC acts via the PTEN tumor suppressor to elicit autoregulation and genome-wide gene repression by activation of the Ezh2 methyltransferase. Cancer Res. 2013, 73:695-705.
18. Kim E., Kim M., Woo D.H., Shin Y., Shin J., Chang N., Oh Y.T., Kim H., Rheey J., Nakano I., et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013, 23:839-852.
19. Kim W., Bird G.H., Neff T., Guo G., Kerenyi M.A., Walensky L.D., Orkin S.H. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat. Chem. Biol. 2013, 9:643-650.
20. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G., Otte A.P., Hayes D.F., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA 2003, 100:11606-11611.
21. Knutson S.K., Wigle T.J., Warholic N.M., Sneeringer C.J., Allain C.J., Klaus C.R., Sacks J.D., Raimondi A., Majer C.R., Song J., et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 2012, 8:890-896.
22. Kodach L.L., Jacobs R.J., Heijmans J., van Noesel C.J., Langers A.M., Verspaget H.W., Hommes D.W., Offerhaus G.J., van den Brink G.R., Hardwick J.C. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis 2010, 31:1567-1575.
23. Koh C.M., Bieberich C.J., Dang C.V., Nelson W.G., Yegnasubramanian S., De Marzo A.M. MYC and prostate cancer. Genes Cancer 2010, 1:617-628.
24. Koh C.M., Iwata T., Zheng Q., Bethel C., Yegnasubramanian S., De Marzo A.M. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2011, 2:669-683.
25. Kondo Y., Shen L., Cheng A.S., Ahmed S., Boumber Y., Charo C., Yamochi T., Urano T., Furukawa K., Kwabi-Addo B., et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 2008, 40:741-750.
26. Lee S.T., Li Z., Wu Z., Aau M., Guan P., Karuturi R.K., Liou Y.C., Yu Q. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Mol. Cell 2011, 43:798-810.
27. Li H., Bitler B.G., Vathipadiekal V., Maradeo M.E., Slifker M., Creasy C.L., Tummino P.J., Cairns P., Birrer M.J., Zhang R. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev. Res. (Phila.) 2012, 5:484-491.
28. Luoto K.R., Meng A.X., Wasylishen A.R., Zhao H., Coackley C.L., Penn L.Z., Bristow R.G. Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res. 2010, 70:8748-8759.
29. Majumder P.K., Sellers W.R. Akt-regulated pathways in prostate cancer. Oncogene 2005, 24:7465-7474.
30. Margueron R., Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349.
31. McCabe M.T., Graves A.P., Ganji G., Diaz E., Halsey W.S., Jiang Y., Smitheman K.N., Ott H.M., Pappalardi M.B., Allen K.E., et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl. Acad. Sci. USA 2012, 109:2989-2994.
32. McCabe M.T., Ott H.M., Ganji G., Korenchuk S., Thompson C., Van Aller G.S., Liu Y., Graves A.P., Della Pietra A., Diaz E., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
33. Melnick A. Epigenetic therapy leaps ahead with specific targeting of EZH2. Cancer Cell 2012, 22:569-570.
34. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42:181-185.
35. Nikoloski G., Langemeijer S.M., Kuiper R.P., Knops R., Massop M., Tönnissen E.R., van der Heijden A., Scheele T.N., Vandenberghe P., de Witte T., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 2010, 42:665-667.
36. Park S.Y., Seol J.W., Lee Y.J., Cho J.H., Kang H.S., Kim I.S., Park S.H., Kim T.H., Yim J.H., Kim M., et al. IFN-gamma enhances TRAIL-induced apoptosis through IRF-1. Eur. J. Biochem. 2004, 271:4222-4228.
37. Popovic R., Licht J.D. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov. 2012, 2:405-413.
38. Qi W., Chan H., Teng L., Li L., Chuai S., Zhang R., Zeng J., Li M., Fan H., Lin Y., et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl. Acad. Sci. USA 2012, 109:21360-21365.
39. Ren G., Baritaki S., Marathe H., Feng J., Park S., Beach S., Bazeley P.S., Beshir A.B., Fenteany G., Mehra R., et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res. 2012, 72:3091-3104.
40. Sander S., Bullinger L., Klapproth K., Fiedler K., Kestler H.A., Barth T.F., Möller P., Stilgenbauer S., Pollack J.R., Wirth T. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008, 112:4202-4212.
41. Sato K., Qian J., Slezak J.M., Lieber M.M., Bostwick D.G., Bergstralh E.J., Jenkins R.B. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J.Natl. Cancer Inst. 1999, 91:1574-1580.
42. Shi B., Liang J., Yang X., Wang Y., Zhao Y., Wu H., Sun L., Zhang Y., Chen Y., Li R., et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol. Cell. Biol. 2007, 27:5105-5119.
43. Sneeringer C.J., Scott M.P., Kuntz K.W., Knutson S.K., Pollock R.M., Richon V.M., Copeland R.A. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. USA 2010, 107:20980-20985.
44. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 2006, 6:846-856.
45. Supino R., Favini E., Cuccuru G., Zunino F., Scovassi A.I. Effect of paclitaxel on intracellular localization of c-Myc and P-c-Myc in prostate carcinoma cell lines. Ann. N Y Acad. Sci. 2007, 1095:175-181.
46. Tan J., Yang X., Zhuang L., Jiang X., Chen W., Lee P.L., Karuturi R.K., Tan P.B., Liu E.T., Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007, 21:1050-1063.
47. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
48. Verma S.K., Tian X., LaFrance L.V., Duquenne C., Suarez D.P., Newlander K.A., Romeril S.P., Burgess J.L., Grant S.W., Brackley J.A. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med. Chem. Lett. 2012, 3:1091-1096.
49. Wolfer A., Ramaswamy S. MYC and metastasis. Cancer Res. 2011, 71:2034-2037.
50. Wolfer A., Wittner B.S., Irimia D., Flavin R.J., Lupien M., Gunawardane R.N., Meyer C.A., Lightcap E.S., Tamayo P., Mesirov J.P., et al. MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc. Natl. Acad. Sci. USA 2010, 107:3698-3703.
51. Xu K., Wu Z.J., Groner A.C., He H.H., Cai C., Lis R.T., Wu X., Stack E.C., Loda M., Liu T., et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 2012, 338:1465-1469.
52. Yap D.B., Chu J., Berg T., Schapira M., Cheng S.W., Moradian A., Morin R.D., Mungall A.J., Meissner B., Boyle M., et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011, 117:2451-2459.
53. Yu J., Cao Q., Mehra R., Laxman B., Yu J., Tomlins S.A., Creighton C.J., Dhanasekaran S.M., Shen R., Chen G., et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007, 12:419-431.
54. Yu J., Cao Q., Yu J., Wu L., Dallol A., Li J., Chen G., Grasso C., Cao X., Lonigro R.J., et al. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene 2010, 29:5370-5380.